Key terms
About NRIX
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NRIX news
Apr 17
7:21am ET
Analysts’ Top Healthcare Picks: Evolent Health (EVH), Nurix Therapeutics (NRIX)
Apr 15
7:11am ET
Nurix Therapeutics (NASDAQ:NRIX) Climbs Higher After Beating Expectations
Apr 12
8:56am ET
Nurix Therapeutics 10.2M share Spot Secondary priced at $15.00
Apr 12
6:12am ET
Nurix Therapeutics 10.2M share Spot Secondary priced at $15.50
Apr 11
4:09pm ET
Nurix Therapeutics $125M Spot Secondary; price range $14.50-$15.50
Apr 11
4:06pm ET
Nurix Therapeutics announces $125M common stock offering
Apr 11
7:18am ET
Nurix Therapeutics price target raised to $23 from $22 at RBC Capital
Apr 11
6:33am ET
Nurix Therapeutics price target raised to $25 from $24 at Baird
Apr 09
8:15pm ET
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Madrigal Pharmaceuticals (MDGL)
Apr 09
6:16am ET
Nurix Therapeutics: A Strong Buy on Innovative Drug Development and Strategic Leadership
Apr 03
4:01am ET
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and DaVita (DVA)
Apr 02
9:15am ET
Nurix Therapeutics Earns ‘Buy’ Rating on Strong Partnerships and Revenue Potential
Apr 02
7:12am ET
Nurix Therapeutics announces extension of collaboration with Gilead
Mar 25
7:07am ET
Nurix Therapeutics part of team selected as Cancer Grand Challenges awardees
Mar 20
9:42am ET
Nurix presents discovery, chemical structure of NX-1607 at ACS meeting
Mar 15
12:03pm ET
JPMorgan biotech/pharma analysts hold an analyst/industry conference call
Mar 12
5:16am ET
Nurix Therapeutics Gains Analyst Confidence with Advancements in Clinical Programs and Strategic Focus on NHL
Mar 11
9:25am ET
Buy Rating Reaffirmed for Nurix Therapeutics Following FDA’s Lift of Clinical Hold on Cancer Drug NX-2127
Mar 11
7:06am ET
Nurix announces FDA lifts partial clinical hold on NX-2127 Phase 1 trial
Feb 29
6:28am ET
Nurix Therapeutics’ Promising Outlook: Buy Rating Affirmed Amidst Strategic Development and Market Positioning
Feb 22
8:50pm ET
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Cochlear Limited (OtherCHEOF) and Nurix Therapeutics (NRIX)
Feb 20
8:00am ET
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL), Biogen (BIIB) and Nurix Therapeutics (NRIX)
Feb 20
6:27am ET
Nurix Therapeutics: Sustained Buy Rating Amidst Financial Reassessment and Promising Clinical Milestones
Feb 20
6:16am ET
Nurix Therapeutics price target lowered to $19 from $35 at H.C. Wainwright
Feb 19
1:11am ET
3 Best Stocks to Buy Now, 2/19/2024, According to Top Analysts
Feb 18
11:47pm ET
Buy Rating Affirmed on Nurix Therapeutics Amid Anticipated Clinical Advancements and Competitive Edge
Feb 16
7:41am ET
Analysts Conflicted on These Healthcare Names: Ultragenyx Pharmaceutical (RARE), Nurix Therapeutics (NRIX) and AMN Healthcare Services (AMN)
Feb 16
7:40am ET
RBC Capital Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)
Feb 16
7:38am ET
Piper Sandler Releases a Buy Rating on Nurix Therapeutics (NRIX)
Feb 16
6:58am ET
Barclays Releases a Buy Rating on Nurix Therapeutics (NRIX)
Feb 16
5:50am ET
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS) and Nurix Therapeutics (NRIX)
No recent press releases are available for NRIX
NRIX Financials
Key terms
Ad Feedback
NRIX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NRIX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
